Human Parvovirus B19 Infection in Pregnancy

Schwarz, TinoF.; Roggendorf, Michael; Hottenträger, Barbara; Deinhardt, Friedrich; Enders, Gisela; Kp, Gloning; Schramm, Thomas; Hansmann, M.

doi:10.1016/s0140-6736(88)92684-0

Cited by 108 publications

(51 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The risk of developing hydrops following this infection is reportedly varied (0 to 24%) (3,91,97,102,117,270,296), but according to recent studies the rate is probably quite low (1 to 1.6%) (123,195,299). However, in pregnant women with a confirmed primary infection, the overall risk of an abnormal outcome is approximately 5 to 10% (91,261,270).…”

Section: B19 Infection In Pregnancy (I) Hydrops Fetalismentioning

confidence: 99%

Human Parvovirus B19

2002

View full text Add to dashboard Cite

Parvovirus B19 (B19) was discovered in 1974 and is the only member of the family Parvoviridae known to be pathogenic in humans. Despite the inability to propagate the virus in cell cultures, much has been learned about the pathophysiology of this virus, including the identification of the cellular receptor (P antigen), and the control of the virus by the immune system. B19 is widespread, and manifestations of infection vary with the immunologic and hematologic status of the host. In healthy immunocompetent individuals B19 is the cause of erythema infectiosum and, particularly in adults, acute symmetric polyarthropathy. Due to the tropism of B19 to erythroid progenitor cells, infection in individuals with an underlying hemolytic disorder causes transient aplastic crisis. In the immunocompromised host persistent B19 infection is manifested as pure red cell aplasia and chronic anemia. Likewise, the immature immune response of the fetus may render it susceptible to infection, leading to fetal death in utero, hydrops fetalis, or development of congenital anemia. B19 has also been suggested as the causative agent in a variety of clinical syndromes, but given the common nature, causality is often difficult to infer. Diagnosis is primarily based on detection of specific antibodies by enzyme-linked immunosorbent assay or detection of viral DNA by dot blot hybridization or PCR. Treatment of persistent infection with immunoglobulin reduces the viral load and results in a marked resolution of anemia. Vaccine phase I trials show promising results

show abstract

Section: B19 Infection In Pregnancy (I) Hydrops Fetalismentioning

confidence: 99%

Human Parvovirus B19

2002

View full text Add to dashboard Cite

show abstract

“…B19-specific IgM antibodies are detected late in the viraemic stage, on about day 10-12 and can persist for up to 5 months postinfection (Anderson et al, 1985;Schwarz et al, 1988;Yaegashi et al, 1989), but in some patients can last even longer (Musiani et al, 1995). B19-specific IgG antibodies appear about 15 days postinfection, remain elevated for many months and generally persist long term (years).…”

Section: Antibody-mediated Immune Responsementioning

confidence: 99%

“…Alternatively, clinical symptoms of infection have been treated effectively by intrauterine blood transfusions (Schwarz et al, 1988;Hansmann et al, 1989). A study by Wattre´reported two cases where intrauterine blood transfusions led to the cessation of symptoms and to the birth of normal babies (Wattre et al, 1998).…”

Section: Treatment and Vaccinationmentioning

confidence: 99%

Human Parvovirus B19: Molecular Virology, Clinical Features, Prevalence, Diagnosis and Control

Corcoran¹,

Doyle²

2006

Congenital and Other Related Infectious Diseases of the Newborn

View full text Add to dashboard Cite

Parvovirus B19-introductionParvovirus B19 (B19) is an erythrovirus and recent studies have classified B19 as a genotype 1 erythrovirus with genotypes 2 (erythrovirus K71 or A6) and 3 (erythrovirus V9) also present in the human population. B19 is a significant human pathogen which can cause foetal hydrops and foetal death if maternal infection, followed by transplacental QA :1 foetal infection, occurs during pregnancy. The virus is also transmitted by inter-personal contact and potentially via blood product administration. Symptoms of B19 infection include malaise, rash and anthralgia. Significantly, maternal B19 infection during pregnancy can be asymptomatic and so careful monitoring of at-risk pregnancies is recommended. Both antibody-and cell-mediated immunity play an important role in the anti-viral response and effective diagnostic test systems, for both B19 antibody and DNA detection, are now available. B19-induced foetal hydrops can be effectively treated by intrauterine blood transfusion; however, no vaccine is available to prevent infection at present.

show abstract

“…AAV has not been found to be associated with disease in humans, nor in laboratory animals (Siegl et al, 1985), in contrast to autonomous parvoviruses some of which are the cause of fetal disorders in humans, [parvovirus B19 Kinney et al, 1988;Schwarz et al, 1988;Torok, 1990;Woernle et al, 1987)] and animals [e.g. porcine parvovirus and minute virus of canines (Carmichael et al, 1991 ;Joo et al, 1976Joo et al, , 1977].…”

Section: Introductionmentioning

confidence: 99%

Adeno-associated virus type 2 interferes with early development of mouse embryos

Botquin

Cid-Arregui

Schlehofer

1994

Journal of General Virology

View full text Add to dashboard Cite

The human helper-dependent adeno-associated virus type 2 (AAV-2) has been shown to induce differentiation in various cell types in culture including pluripotent embryonic cells, in the absence of helper virus. To assess whether induction of differentiation may influence developmental processes we analysed the effect of AAV-2 on developing mouse embryos. In vitro infection of fertilized eggs induced arrest of development at the twocell stage. Moreover, micro injection of AAV-2 DNA (comprising either the complete AAV-2 genome or a fragment containing the P5 promoter region) into onecell embryos, blocked development at the morula stage. In vivo, AAV-2 infection of pregnant mice led to fetal death and early abortion. These results demonstrate that the human adeno-associated virus, which is thought to be non-pathogenic, can perturb embryonic development in mice. This may provide a suitable animal model system to further elucidate the biological significance of the recent detection of adeno-associated virus DNA in human abortion material.

show abstract

Human Parvovirus B19 Infection in Pregnancy

Cited by 108 publications

References 10 publications

Human Parvovirus B19

Human Parvovirus B19

Human Parvovirus B19: Molecular Virology, Clinical Features, Prevalence, Diagnosis and Control

Adeno-associated virus type 2 interferes with early development of mouse embryos

Contact Info

Product

Resources

About